HYDERGINE
LOE ApproachingNDAORALSOLUTION
Approved
Jan 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is an oral solution small-molecule NDA approved in 1981 by Novartis with an undisclosed mechanism of action and indication profile. The drug is currently approaching loss of exclusivity, indicating it is a legacy product in late-stage market maturity.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely focused on lifecycle extension and managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDERGINE currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Career opportunities on this product are limited and typically defensive in nature, focusing on profit protection rather than expansion.
Brand ManagerField Sales Representative
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.